{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:29:23Z","timestamp":1793212163968,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"7","funder":[{"name":"Santarus, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"DOI":"10.1093\/ecco-jcc\/jjx032","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T20:11:37Z","timestamp":1488571897000},"page":"785-791","source":"Crossref","is-referenced-by-count":72,"title":["Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial"],"prefix":"10.1093","volume":"11","author":[{"given":"David T.","family":"Rubin","sequence":"first","affiliation":[{"name":"Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell D.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of California [UC] San Diego and UC San Diego Health System, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"Lichtenstein","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Axler","sequence":"additional","affiliation":[{"name":"Toronto Digestive Disease Associates, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Riddell","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Mt Sinai Hospital, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Zhu","sequence":"additional","affiliation":[{"name":"Salix Pharmaceuticals, Raleigh, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Barrett","sequence":"additional","affiliation":[{"name":"Salix Pharmaceuticals, Raleigh, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enoch","family":"Bortey","sequence":"additional","affiliation":[{"name":"Salix Pharmaceuticals, Raleigh, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Forbes","sequence":"additional","affiliation":[{"name":"Salix Pharmaceuticals, Raleigh, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,3,4]]},"reference":[{"key":"key\n\t\t\t\t20180315032311_CIT0001","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ord\u00e1s","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180315032311_CIT0002","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180315032311_CIT0003","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management","volume":"6","author":"Dignass","year":"2012","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180315032311_CIT0004","first-page":"86","article-title":"Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid","volume":"122","author":"Ryrfeldt","year":"1982","journal-title":"Eur J Respir Dis Suppl"},{"key":"key\n\t\t\t\t20180315032311_CIT0005","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1155\/1990\/708916","article-title":"Overview of newer glucocorticosteroid preparations for inflammatory bowel disease","volume":"4","author":"Brattsand","year":"1990","journal-title":"Can J Gastroenterol"},{"key":"key\n\t\t\t\t20180315032311_CIT0006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2125.2005.02517.x","article-title":"Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation","volume":"61","author":"Brunner","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180315032311_CIT0007","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2174\/092986710791111170","article-title":"New drug delivery systems in inflammatory bowel disease: MMX\u2122 and tailored delivery to the gut","volume":"17","author":"Fiorino","year":"2010","journal-title":"Curr Med Chem"},{"key":"key\n\t\t\t\t20180315032311_CIT0008","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2012.08.003","article-title":"Once-daily budesonide MMX\u00ae extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032311_CIT0009","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/gutjnl-2012-304258","article-title":"Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study","volume":"63","author":"Travis","year":"2014","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180315032311_CIT0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.crohns.2009.09.007","article-title":"Clinical trial: Preliminary efficacy and safety study of a new budesonide-MMX\u00ae 9 mg extended-release tablets in patients with active left-sided ulcerative colitis","volume":"4","author":"D\u2019Haens","year":"2010","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180315032311_CIT0011","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/apt.12712","article-title":"Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis","volume":"39","author":"Danese","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180315032311_CIT0012","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/0016-5085(87)90621-4","article-title":"5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis","volume":"92","author":"Sutherland","year":"1987","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032311_CIT0013","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.47.3.404","article-title":"A reproducible grading scale for histological assessment of inflammation in ulcerative colitis","volume":"47","author":"Geboes","year":"2000","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180315032311_CIT0014","volume-title":"North Ryde, NSW: Novartis Pharmaceuticals","author":"Synacthen\n            \n              \u00ae\n            \n            [tetracosactrin]","year":"2012"},{"key":"key\n\t\t\t\t20180315032311_CIT0015","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/0016-5085(87)90554-3","article-title":"Studies on the mechanism of bowel disturbance in ulcerative colitis","volume":"93","author":"Rao","year":"1987","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032311_CIT0016","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.cgh.2013.02.030","article-title":"Histologic markers of inflammation in patients with ulcerative colitis in clinical remission","volume":"11","author":"Rosenberg","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180315032311_CIT0017","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ajg.2015.120","article-title":"C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis","volume":"110","author":"Mosli","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180315032311_CIT0018","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180315032311_CIT0019","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/j.gastro.2014.08.003","article-title":"Converging goals of treatment of inflammatory bowel disease from clinical trials and practice","volume":"148","author":"Levesque","year":"2015","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032311_CIT0020","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.giec.2014.03.005","article-title":"Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity","volume":"24","author":"Walsh","year":"2014","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"key\n\t\t\t\t20180315032311_CIT0021","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","article-title":"Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort","volume":"133","author":"Fr\u00f8slie","year":"2007","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315032311_CIT0022","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.crohns.2014.08.011","article-title":"Systematic review: histological remission in inflammatory bowel disease. Is \u2018complete\u2019 remission the new treatment paradigm? An IOIBD initiative","volume":"8","author":"Bryant","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180315032311_CIT0023","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2013.03.025","article-title":"The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis","volume":"145","author":"Feagan","year":"2013","journal-title":"Gastroenterology"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/11\/7\/785\/24365606\/jjx032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T07:23:22Z","timestamp":1521098602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/11\/7\/785\/3061890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,4]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,3,4]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx032","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7]]},"published":{"date-parts":[[2017,3,4]]}}}